Welcome to our dedicated page for Inventiva S.A. SEC filings (Ticker: IVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inventiva S.A. filings document a foreign private issuer and ADR program tied to a clinical-stage biopharmaceutical company developing oral therapies for MASH. Form 6-K reports furnish press releases and meeting notices covering lanifibranor development, annual and preliminary financial results, R&D expense trends, cash resources, revenues, and financing activity.
The company's regulatory disclosures also cover governance and shareholder voting matters, annual general meeting materials, leadership and organizational changes, material agreements, capital-structure disclosures, and portfolio actions including the completed sale of odiparcil. These records connect Inventiva's drug-development focus with its reporting obligations as a France-based issuer listed through American depositary shares.
Inventiva S.A. reported certain preliminary, unaudited figures for 2025, highlighting a strengthened cash position following major financings. As of December 31, 2025, cash and cash equivalents were €99.3 million and short-term deposits were €131.6 million, supporting the company’s MASH-focused clinical pipeline.
Net cash used in operating activities rose to (€104.6) million from (€85.9) million, driven by pipeline prioritization, lower licensing revenues from CTTQ, and higher general and administrative expenses, while R&D expenses decreased slightly to €86.9 million from €90.9 million. Net cash used in investing activities was (€133.2) million, mainly from new short-term deposits.
Net cash generated by financing activities reached €241.1 million, including €115.6 million of gross proceeds from the second tranche of a structured financing and $172.5 million of gross proceeds from a U.S. public offering. Revenues declined to €4.5 million from €9.2 million in 2024. Based on its current plan, Inventiva estimates its cash, cash equivalents, and short-term deposits can fund operations until the middle of the first quarter of 2027, with a potential extension to the middle of the third quarter of 2027 if Tranche 3 warrants are fully exercised.
Eventide Asset Management, LLC, together with Finny Kuruvilla and Robin C. John, reports beneficial ownership of 9,368,517 Inventiva S.A. ordinary shares, representing 4.6% of the class as of December 31, 2025.
Eventide has sole voting and dispositive power over 9,368,517 shares, while Kuruvilla and John share voting and dispositive power over the same amount. The group files as passive investors, certifying the holdings are not for changing or influencing control, and expressly disclaims beneficial ownership under Rule 13d-4.
Deep Track Capital, its master fund, and David Kroin have filed a Schedule 13G reporting a significant passive stake in Inventiva S.A. They report beneficial ownership of 11,668,983 ordinary shares and related instruments, representing 6.07% of the class as of January 30, 2026, based on 192,329,222 shares outstanding as of December 31, 2025.
The position includes 8,504,604 ordinary shares, 3,164,379 American Depository Shares and 9,999,999 warrants with a 1.50 EUR exercise price. The warrants are exercisable only if a “T3 Triggering Event” occurs, tied to NATiV3 trial topline results meeting key endpoints by June 15, 2027, and must be exercised no later than July 30, 2027. A 4.99% beneficial ownership cap limits how much can be held through warrant exercise.
The filers certify the securities are not held to change or influence control of Inventiva S.A. and characterize themselves as passive investors under Schedule 13G.
Inventiva S.A. announced an underwritten public offering of 38,961,038 ADSs at $3.85 per ADS, with a 30‑day option for underwriters to purchase up to 5,844,155 additional ADSs. The company expects net proceeds of approximately $140.1 million, or $161.2 million if the option is exercised in full, after underwriting commissions and estimated expenses.
The offering is being conducted under Inventiva’s Form F‑3 shelf that was deemed effective on November 3, 2025, and is expected to close on November 17, 2025, subject to customary closing conditions. Leerink Partners LLC and Piper Sandler & Co. are acting as underwriters. A legal opinion from Gide Loyrette Nouel A.A.R.P.I. has been filed in support of the issuance.
Inventiva S.A. (IVA) launched a primary offering of 38,961,038 American Depositary Shares at $3.85 per ADS under its shelf registration. The pricing implies a total offering size of $149,999,996, with underwriting commissions of $8,999,999 and estimated net proceeds of approximately $140.1 million. The company also granted underwriters a 30‑day option to purchase up to 5,844,155 additional ADSs at the public offering price, less commissions.
Inventiva plans to use roughly 80% of the proceeds to fund its NATiV3 Phase 3 MASH trial, prepare and initiate an outcomes trial, and support commercialization activities, and about 20% for working capital and general corporate purposes. Ordinary shares outstanding are expected to be 178,112,312 after the offering, or 183,956,467 if the option is fully exercised. The company notes immediate dilution of $3.12 per ADS to new investors.
Inventiva S.A. launched a preliminary prospectus supplement for a $125,000,000 primary offering of American Depositary Shares (ADSs), each representing one ordinary share. The ADSs trade on Nasdaq under “IVA,” and the ordinary shares trade on Euronext Paris as “IVA.”
The company states it will receive the proceeds and has granted underwriters a 30‑day option to purchase additional ADSs. Intended uses include funding the NATiV3 Phase 3 MASH program, preparation/initiation of an outcomes trial, commercialization activities, and general corporate purposes.
As context, cash and cash equivalents were €97.6 million and short‑term deposits were €24.7 million as of September 30, 2025. Ordinary shares outstanding were 139,151,274 as of June 30, 2025, and 146,272,305 as of November 10, 2025. The company discloses it expects to finance activities until the end of Q3 2026 and notes a material uncertainty that may cast significant doubt on its ability to continue as a going concern.
Inventiva S.A. announced its Ordinary and Extraordinary General Meeting, publishing the official notice on November 7, 2025. The meeting will take place on November 27, 2025 at 9 a.m. at Hôtel Villa M, 24-30 boulevard Pasteur, 75015 Paris, France.
The notice of meeting is furnished as Exhibit 99.1 to this Form 6-K and, as stated, is being furnished and not deemed filed under the Exchange Act.